Lamotrigine and Distributive shock - a phase IV clinical study of FDA data

Summary:

Distributive shock is reported as a side effect among people who take Lamotrigine (lamotrigine), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Sertraline, and have Hepatitis c.

The phase IV clinical study analyzes which people have Distributive shock when taking Lamotrigine. It is created by eHealthMe based on reports of 72,834 people who have side effects when taking Lamotrigine from the FDA, and is updated regularly.

What is Lamotrigine?

Lamotrigine has active ingredients of lamotrigine. It is often used in bipolar disorder. eHealthMe is studying from 76,639 Lamotrigine users. Check the latest studies of Lamotrigine.

What is Distributive shock?

Distributive shock (hock caused by poor distribution of the blood flow) is found to be associated with 116 drugs and 123 conditions by eHealthMe. Check the latest studies of Distributive shock.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

72,834 people reported to have side effects when taking Lamotrigine.
Among them, 77 people (0.11%) have Distributive shock.

Could Lamotrigine cause Distributive shock?

Among these 77 people:

How long have people been on Lamotrigine when they have Distributive shock? *

What is the gender of people who have Distributive shock when taking Lamotrigine? *

female: 69.49 %
male: 30.51 %

What is the age of people who have Distributive shock when taking Lamotrigine? *

What are other drugs people take besides Lamotrigine? *

Sertraline: 24 people, 31.17%
Zopiclone: 20 people, 25.97%
Hydroxyzine: 20 people, 25.97%
Propranolol Hydrochloride: 16 people, 20.78%
Viekira Pak: 13 people, 16.88%
Sodium Bicarbonate: 8 people, 10.39%
Amlodipine: 3 people, 3.90%
Carbamazepine: 3 people, 3.90%
Hydroxyzine Hydrochloride: 3 people, 3.90%
Gabapentin: 3 people, 3.90%

What are other side effects people have besides Distributive shock? *

Hypotension (abnormally low blood pressure): 28 people, 36.36%
Electrocardiogram Qt Prolonged: 26 people, 33.77%
Consciousness - Decreased: 25 people, 32.47%
Hypokalemia (low potassium): 23 people, 29.87%
Electrocardiogram Qrs Complex Prolonged: 19 people, 24.68%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 19 people, 24.68%
Electrocardiogram St Segment Depression: 18 people, 23.38%
Overdose: 18 people, 23.38%
Bradypnea: 16 people, 20.78%
Cerebral Disorder (brain disease): 16 people, 20.78%

What are the existing conditions these people have? *

Suicide Attempt: 12 people, 15.58%
Hepatitis C: 12 people, 15.58%
Depression: 5 people, 6.49%
Overdose: 2 people, 2.60%
Status Epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure): 1 person, 1.30%
Rickets (softening of bones): 1 person, 1.30%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 1.30%
Electrocardiogram Qrs Complex Prolonged: 1 person, 1.30%
Diabetes: 1 person, 1.30%

* Approximation only. Some reports may have incomplete information.

Do you take Lamotrigine and have Distributive shock?

- Check whether Distributive shock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lamotrigine:

Lamotrigine (76,639 reports)

Browse all side effects of Lamotrigine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Distributive shock:

Distributive shock (116 drugs)

Browse all the conditions that are associated with Distributive shock:

Distributive shock (123 conditions)

Related publications that referenced our studies

Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lamotrigine (the active ingredients of Lamotrigine) and Lamotrigine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.